GI & Endoscopy

  Here are seven updates on GI companies and practices over the past week:

The American College of Gastroenterology released its first clinical guideline on the management of irritable bowel syndrome, published in The American Journal of Gastroenterology Dec. 14.

Emerging research supports non-biopsy diagnostic testing for celiac disease, according to a Dec. 14 report on Celiac.com.

A large group purchasing organization entered into a contract with Ambu for access to its single-use endoscope products, the company announced Dec. 14.

Austin Chiang, MD, has made social media a staple of his career, and now as the U.S. begins COVID-19 vaccine distribution, Jefferson Health's chief social media officer is doubling down on his efforts, The New York Times reported Dec. 14. 

Awareness of a patient's positive fecal immunochemical test or triennial multitarget stool DNA test increased adenoma detection rates among endoscopists, according to an early view study published Dec. 14 in Cancer Medicine.

The Digestive Health Physicians Association issued a statement opposing CMS' Most Favored Nation rule because it potentially limits access to infusion services.

Gastroenterologists recommend patients with inflammatory bowel disease seek out the COVID-19 vaccine as soon as they become available, Medscape reported Dec. 11.

A new transitional pass-through code (C1748) took effect July 1 for providers using single-use duodenoscopes to treat Medicare patients in the hospital outpatient and ambulatory surgical center (ASC) settings. The pass-through code makes single-use duodenoscopes a financially viable alternative to…

Jacksonville-based Digestive Disease Consultants will open a 14,377-square-foot surgery center in Orange Park, Fla., in 2021, the Jacksonville Daily Record reported Dec. 14.